Prevnar 20® (pneumococcal 20-valent conjugate vaccine) – New indications

- On April 27, 2023, Pfizer announced the FDA approval of Prevnar 20 (pneumococcal 20-valent conjugate vaccine), for active immunization for the prevention of:
    - Invasive disease caused by *Streptococcus pneumoniae* (*S. pneumoniae*) serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 6 weeks of age and older
    - Otitis media caused by *S. pneumoniae* serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F in individuals 6 weeks through 5 years of age.

- Prevnar 20 is also approved for active immunization for the prevention of pneumonia caused by *S. pneumoniae* serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F in individuals 18 years of age and older.

- Prevnar 20 builds on Prevnar 13® for the pediatric population and includes seven additional serotypes shown to be associated with antibiotic resistance, heightened disease severity, invasive potential, and prevalence in pediatric pneumococcal cases.

- The approval of Prevnar 20 for the expanded indication was based on results from the Phase 2 and Phase 3 clinical trial programs for the pediatric indication for Prevnar 20. Three core Phase 3 pediatric studies contributed to data on the safety, tolerability, and immunogenicity of Prevnar 20.
    - For complete clinical results, refer to the Prevnar 20 drug label.

- For individuals 6 weeks through 15 months of age, Prevnar 20 should be administered via intramuscular injection as a 4-dose series at 2, 4, 6, and 12 through 15 months of age (and at least 2 months after the third dose). The first dose may be given as early as 6 weeks of age.
    - Refer to the Prevnar 20 drug label for the catch-up vaccination schedule in pediatric patients and for dosing in adults.